Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Lenalidomide has been approved by the US Food and Drug Administration for the treatment of patients with myelodysplastic syndromes (MDS) with an interstitial deletion of the long arm of chromosome 5 and, more recently, in combination with dexamethasone for multiple myeloma in patients who received at least one prior therapy. This discussion examines several clinically relevant, practical considerations regarding dosing, monitoring, follow-up evaluation, adverse events, and available support for lenalidomide recipients and their prescribing physicians in the MDS setting.
Kurtin
Sandra
S
University of Arizona, Arizona Cancer Center, Tucson, 85724, USA. skurtin@umcaz.edu
Sokol
Lubomir
L
D000740:Anemia / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D000077269:Lenalidomide; D008495:Medical Oncology / Q000639:trends; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide